Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$799M in Q4 2025 → $602M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Crispr Therapeutics Ag | 29.2% | Unchanged | 3,220,627 | $176M |
| Wave Life Sciences Ltd | 17.6% | Unchanged | 18,245,691 | $106M |
| Vir Biotechnology Inc | 14.5% | Unchanged | 8,550,954 | $87.1M |
| Biontech Se | 13.7% | Unchanged | 889,824 | $82.8M |
| Ideaya Biosciences Inc | 8.3% | Unchanged | 1,333,333 | $49.7M |
| Cytokinetics Inc | 4.8% | Unchanged | 340,434 | $29M |
| Lyell Immunopharma Inc | 3.5% | Unchanged | 1,512,659 | $21.3M |
| Spero Therapeutics Inc | 3.4% | Unchanged | 9,190,606 | $20.3M |
| Nkarta Inc | 1.5% | Unchanged | 3,150,732 | $8.92M |
| Fulcrum Therapeutics Inc | 1.1% | Unchanged | 1,785,714 | $6.54M |
| Bicycle Therapeutics PLC | 1.1% | Unchanged | 1,529,561 | $6.49M |
| Cvrx Inc | 0.9% | Unchanged | 1,007,583 | $5.18M |
| Regenxbio Inc | 0.5% | Unchanged | 271,456 | $3.25M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 13, 2026
No position changes this quarter.
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SH Senseonics Hldgs Inc | Exited | −10,856 | −$59.9K | — |
| Harvard Bioscience Inc | Exited | −11,151 | −$7.46K | — |
Loading...
